NEFROMEDA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,415,458 | 1,431,280 | 1,512,826 | 1,287,487 | 1,537,170 | 1,600,118 | 1,667,836 | 1,598,054 |
| Profit before tax | 104,006 | 5,705 | 98,776 | 33,595 | 86,122 | 26,866 | 98,462 | 61,883 |
| Net profit | 104,006 | 5,705 | 98,776 | 33,595 | 86,122 | 26,866 | 98,462 | 51,595 |
| Equity | 358,434 | 304,139 | 312,915 | 306,510 | 362,632 | 309,498 | 327,960 | 309,555 |
| Liabilities | 96,445 | 112,704 | 94,080 | 111,033 | 88,778 | 70,162 | 92,785 | 90,056 |
| Non-current assets | 194,254 | 182,759 | 161,223 | 147,521 | 104,436 | 67,638 | 92,482 | 66,398 |
| Current assets | 260,625 | 234,084 | 245,772 | 270,022 | 346,974 | 312,022 | 325,233 | 333,321 |
| Total assets | 454,879 | 416,843 | 406,995 | 417,543 | 451,410 | 379,660 | 417,715 | 399,719 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 196,972 | 189,135 | 178,010 |
| Social insurance contributions | - | - | - | - | - | 230,086 | 226,127 | 217,677 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +7.5% | +1.1% | +5.7% | -14.9% | +19.4% | +4.1% | +4.2% | -4.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 22.9% | 1.4% | 24.3% | 8.0% | 19.1% | 7.1% | 23.6% | 12.9% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 29.0% | 1.9% | 31.6% | 11.0% | 23.7% | 8.7% | 30.0% | 16.7% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 7.3% | 0.4% | 6.5% | 2.6% | 5.6% | 1.7% | 5.9% | 3.2% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 7.3% | 0.4% | 6.5% | 2.6% | 5.6% | 1.7% | 5.9% | 3.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | 0.4 | 0.3 | 0.4 | 0.2 | 0.2 | 0.3 | 0.3 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 33,175 | 33,876 | 36,601 | 31,725 | 39,754 | 43,640 | 46,115 | 45,228 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
NEFROMEDA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-03-27 | 2026-03-27 | 255.48 |
| 2026-03-17 | 2026-03-24 | 255.48 |
NEFROMEDA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-03-11 | 2026-03-27 | 0.06 |
| 2026-02-27 | 2026-03-10 | 0.1 |
| 2026-02-21 | 2026-02-26 | 209.1 |
| 2025-05-09 | 2025-05-12 | 1.65 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
NEFROMEDA, UAB (code 148369887) is a Private Limited Liability Company engaged in medical specialists activities. In the latest financial year, 2025, the company generated revenue of EUR 1.60 million and net profit of EUR 51.6 thousand, giving a profit margin of 3.2%. Revenue declined by 4.2% year on year, while the two-year change was broadly flat at -0.1%, indicating a relatively stable top line over the period. Profitability improved sharply in 2024 before easing in 2025: net profit rose from EUR 26.9 thousand in 2023 to EUR 98.5 thousand in 2024, then moderated to EUR 51.6 thousand in 2025. At year-end 2025, total assets stood at EUR 399.7 thousand, equity at EUR 309.6 thousand and liabilities at EUR 90.1 thousand, showing a strong equity position and a debt-to-equity ratio of 0.29. The company reported return on equity of 16.7% and return on assets of 12.9%, with asset turnover of 4.00x. Revenue per employee was EUR 45.7 thousand, while profit per employee was EUR 1.5 thousand.